Sanofi and Aventis to link up comms units after merger

PARIS and NEW YORK: Sanofi-Synthelabo's bid for Aventis Pharmaceuticals also will bring about a merger between the drug companies' communications departments.

PARIS and NEW YORK: Sanofi-Synthelabo's bid for Aventis Pharmaceuticals also will bring about a merger between the drug companies' communications departments.

PR executives from all global affiliate offices will report to Nicole Cranois, who was appointed on June 22 to a management committee that is made up of eight Sanofi and 10 Aventis representatives.

Cranois is currently SVP of corporate communications at Sanofi's Paris headquarters.

The management committee will report to Jean-Francois Dehecq, Sanofi's current chairman and CEO, who will remain in that position following the acquisition.

"The communications departments of Sanofi and Aventis will effectively merge," said Joelle Sissmann, VP of US communications in Sanofi's New York office.

Sissmann declined to discuss whether the merger would eliminate or relocate any staff positions.

Sanofi also announced that the closing date on the offer has been postponed one month to July 30.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.